Inhibition of VCP has been tested in diverse cancer cell lines and tumor models: CB-5083 has been suggested to decrease cell growth in MM [11], acute lymphoblastic leukemia (ALL) [12], and lymphoma [13, 14]. Here, VCP is linked to acute lymphoblastic leukemia.